MX383808B - Formulacion estable de proteina en solucion que contiene una alta concentracion de un anticuerpo anti-vegf. - Google Patents

Formulacion estable de proteina en solucion que contiene una alta concentracion de un anticuerpo anti-vegf.

Info

Publication number
MX383808B
MX383808B MX2017005874A MX2017005874A MX383808B MX 383808 B MX383808 B MX 383808B MX 2017005874 A MX2017005874 A MX 2017005874A MX 2017005874 A MX2017005874 A MX 2017005874A MX 383808 B MX383808 B MX 383808B
Authority
MX
Mexico
Prior art keywords
high concentration
protein solution
formulation containing
vegf antibody
solution formulation
Prior art date
Application number
MX2017005874A
Other languages
English (en)
Spanish (es)
Other versions
MX2017005874A (es
Inventor
Alok Kulshreshtha
Charles Boring
Huixiang Zhang
Laman Alani
Li Wang
Yuhong Zeng
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54697654&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX383808(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2017005874A publication Critical patent/MX2017005874A/es
Publication of MX383808B publication Critical patent/MX383808B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
    • A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
    • A61B3/12—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Medical Informatics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2017005874A 2014-11-07 2015-11-06 Formulacion estable de proteina en solucion que contiene una alta concentracion de un anticuerpo anti-vegf. MX383808B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462076770P 2014-11-07 2014-11-07
US201462088061P 2014-12-05 2014-12-05
PCT/US2015/059571 WO2016073915A1 (en) 2014-11-07 2015-11-06 Stable protein solution formulation containing high concentration of an anti-vegf antibody

Publications (2)

Publication Number Publication Date
MX2017005874A MX2017005874A (es) 2017-06-26
MX383808B true MX383808B (es) 2025-03-14

Family

ID=54697654

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2017005874A MX383808B (es) 2014-11-07 2015-11-06 Formulacion estable de proteina en solucion que contiene una alta concentracion de un anticuerpo anti-vegf.
MX2017005875A MX383399B (es) 2014-11-07 2015-11-06 Un antagonista anti-vegf para usarse en el tratamiento de enfermedades oculares.
MX2021006768A MX2021006768A (es) 2014-11-07 2017-05-04 Metodos para tratar enfermedades oculares.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2017005875A MX383399B (es) 2014-11-07 2015-11-06 Un antagonista anti-vegf para usarse en el tratamiento de enfermedades oculares.
MX2021006768A MX2021006768A (es) 2014-11-07 2017-05-04 Metodos para tratar enfermedades oculares.

Country Status (25)

Country Link
US (5) US10035850B2 (show.php)
EP (2) EP3215123A1 (show.php)
JP (6) JP6667519B2 (show.php)
KR (4) KR20240161204A (show.php)
CN (4) CN106999581A (show.php)
AU (6) AU2015342818B2 (show.php)
BR (2) BR112017008093A2 (show.php)
CA (1) CA2966646A1 (show.php)
CL (2) CL2017001117A1 (show.php)
CO (1) CO2017004596A2 (show.php)
EA (1) EA201790989A1 (show.php)
EC (1) ECSP17034829A (show.php)
ES (1) ES3051145T3 (show.php)
GT (1) GT201700096A (show.php)
IL (5) IL251642B (show.php)
MX (3) MX383808B (show.php)
MY (2) MY183807A (show.php)
NZ (1) NZ730821A (show.php)
PE (1) PE20170780A1 (show.php)
PH (3) PH12021550147A1 (show.php)
RU (1) RU2722643C2 (show.php)
SG (3) SG11201702954XA (show.php)
TN (1) TN2017000128A1 (show.php)
TW (4) TWI738632B (show.php)
WO (2) WO2016073918A1 (show.php)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007237096C1 (en) 2006-04-07 2012-12-13 EyePoint, Inc. Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
EP2307458B1 (en) 2008-06-25 2018-04-11 ESBATech, an Alcon Biomedical Research Unit LLC Humanization of rabbit antibodies using a universal antibody framework
HUE053548T2 (hu) 2008-06-25 2021-07-28 Novartis Ag Stabil és szolúbilis, TNF-gátló ellenanyagok
TR201907783T4 (tr) 2009-07-06 2019-06-21 Aerpio Therapeutics Inc Benzosulfonamit türevleri, bileşimleri ve kanser hücrelerinin metastazının önlenmesinde kullanımları.
EP2663325A1 (en) 2011-01-13 2013-11-20 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat angiogenic eye disorders
EP2766043A4 (en) 2011-10-13 2015-06-10 Aerpio Therapeutics Inc METHOD FOR THE TREATMENT OF CAPILLARY LECKSYNDROME AND CANCER
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
CN106456614A (zh) 2014-03-14 2017-02-22 爱尔皮奥治疗有限公司 HPTP‑β抑制剂
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
TWI738632B (zh) 2014-11-07 2021-09-11 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
CN107206080B (zh) 2015-01-28 2022-07-08 辉瑞公司 稳定的水性抗血管内皮细胞生长因子(vegf)抗体制剂
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
EP3977994B1 (en) 2015-09-23 2024-04-24 EyePoint Pharmaceuticals, Inc. Activators of tie-2 for use in treating intraocular pressure
NZ782855A (en) 2015-12-04 2025-08-29 Novartis Ag Compositions and methods for immunooncology
CN108712911A (zh) 2015-12-30 2018-10-26 科达制药股份有限公司 抗体及其缀合物
MX2019000727A (es) 2016-07-20 2019-05-02 Aerpio Therapeutics Inc Anticuerpos monoclonales humanizados que tienen como blanco ve-ptp (hptp-b).
US11254738B2 (en) * 2016-09-07 2022-02-22 The Governing Council Of The University Of Toronto Banting Institute Synthetic antibodies against VEGF and their uses
EP3518971A4 (en) * 2016-09-28 2020-05-13 Board Of Regents, The University Of Texas System ANTIBODIES AND THERAPEUTIC PROTEIN FORMULATIONS AND USES THEREOF
RU2767793C2 (ru) 2016-11-18 2022-03-21 Астеллас Фарма Инк. НОВЫЙ Fab-ФРАГМЕНТ АНТИТЕЛА ПРОТИВ MUC1 ЧЕЛОВЕКА
EP3601561A2 (en) 2017-03-22 2020-02-05 Novartis AG Compositions and methods for immunooncology
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
WO2018195912A1 (zh) * 2017-04-28 2018-11-01 苏州思坦维生物技术股份有限公司 一种眼用药物组合物及其用途
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
WO2019020777A1 (en) * 2017-07-26 2019-01-31 Formycon Ag LIQUID FORMULATION OF A VEGF ANTAGONIST
SG11202002489YA (en) 2017-10-06 2020-04-29 Prothena Biosciences Ltd Anti-transthyretin antibodies
BR112020006791A2 (pt) 2017-10-06 2020-12-01 Prothena Biosciences Limited métodos de detecção de transtirretina
CN111433223B (zh) * 2017-11-29 2024-08-27 诺和诺德A/S（股份有限公司） 抗甲状腺素运载蛋白单克隆抗体的冻干制剂
KR20240074890A (ko) 2017-11-30 2024-05-28 리제너론 파아마슈티컬스, 인크. 혈관형성 눈 장애를 치료하기 위한 vegf 길항제의 용도
EA202091786A1 (ru) 2018-01-26 2020-10-20 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Способы и композиции для лечения ангиогенных расстройств с применением агентов против фрэс
KR20250166355A (ko) * 2018-02-06 2025-11-27 에프. 호프만-라 로슈 아게 안과 질환의 치료
BR112020017872A2 (pt) 2018-03-02 2020-12-22 Kodiak Sciences Inc. Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
KR20200131839A (ko) * 2018-03-16 2020-11-24 노파르티스 아게 안질환의 치료 방법
TW202003036A (zh) * 2018-03-23 2020-01-16 德商艾伯維德國有限及兩合公司 穩定水性抗-tau抗體調配物
CN112262158B (zh) * 2018-04-10 2024-08-09 奥美药业有限公司 新型血管生成素2，vegf双特异性拮抗剂
MX421310B (es) 2018-05-10 2025-03-14 Regeneron Pharma Formulaciones que contienen proteína de fusión del receptor de vegf a alta concentración
CN112135841A (zh) 2018-05-17 2020-12-25 安斯泰来制药株式会社 包含抗人MUC1抗体Fab片段、肽接头和/或配体的复合物
US10894824B2 (en) 2018-09-24 2021-01-19 Aerpio Pharmaceuticals, Inc. Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF
TW202027794A (zh) 2018-10-03 2020-08-01 瑞士商諾華公司 血管生成素樣３多肽之持續遞送
US12065503B2 (en) * 2018-10-10 2024-08-20 Astellas Pharma Inc. Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
CN119033685A (zh) * 2018-10-29 2024-11-29 豪夫迈·罗氏有限公司 抗体制剂
JP7487193B2 (ja) 2018-11-07 2024-05-20 アプライド モレキュラー トランスポート インコーポレイテッド 異種ペイロードの経口送達のためのコリックス由来担体
JP7089121B2 (ja) * 2018-12-18 2022-06-21 ノバルティス アーゲー 高濃度の抗ｖｅｇｆ抗体を含有するタンパク質溶液製剤
PE20212185A1 (es) 2019-02-18 2021-11-11 Lilly Co Eli Formulacion de anticuerpos terapeuticos
TW202532428A (zh) 2019-04-26 2025-08-16 美商愛德維仁生物科技公司 用於玻璃體內遞送之變異體aav蛋白殼
AU2020264969B2 (en) 2019-04-29 2025-06-05 EyePoint, Inc. Tie-2 activators targeting the schlemm's canal
EP3844169B1 (en) 2019-08-16 2025-10-01 Thornhill Therapeutics, Inc. Compositions, formulations, and interleukin production and purification
CN114786731A (zh) * 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
MX2022006241A (es) 2019-11-25 2022-08-22 Univ California Inhibidores de vegf de accion prolongada para la neovascularizacion intraocular.
CN111217834B (zh) * 2020-02-21 2021-10-26 维眸生物科技（上海）有限公司 Rock激酶抑制剂的硝基氧衍生物
BR112022015627A2 (pt) * 2020-03-04 2022-09-27 Shanghai Henlius Biotech Inc Formulação farmacêutica que compreende bevacizumabe
WO2021233408A1 (zh) * 2020-05-21 2021-11-25 迈威(上海)生物科技股份有限公司 抗α-溶血素的抗体及其稳定制剂
KR20220001106A (ko) * 2020-06-29 2022-01-05 (주)메디톡스 고농도 항-ｖｅｇｆ 항체 제제 및 이에 사용하기 위한 항-ｖｅｇｆ 항체
EP4182025A1 (en) 2020-07-16 2023-05-24 Novartis AG Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
PL4185318T3 (pl) * 2021-05-17 2026-01-12 Regeneron Pharmaceuticals, Inc. Rozszerzone schematy leczenia dużymi dawkami antagonistów vegf w leczeniu angiogennych zaburzeń oka
CN113940997B (zh) * 2021-12-21 2022-04-08 迈威(上海)生物科技股份有限公司 一种双特异性抗体的稳定制剂
WO2024056058A1 (zh) * 2022-09-16 2024-03-21 齐鲁制药有限公司 一种稳定的高浓度自缓冲药物组合物
WO2025231345A1 (en) * 2024-05-03 2025-11-06 Therini Bio, Inc. Doses of antibodies which bind human fibrin yc or fibrinogen yc domain for ocular diseases

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
SI1802334T1 (sl) 2004-10-21 2012-12-31 Genentech, Inc. Postopek za zdravljenje intraokularnih neovaskularnih bolezni
WO2007011873A2 (en) * 2005-07-15 2007-01-25 Genentech, Inc. Method for treating intraocular neovascular diseases
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
KR101406811B1 (ko) 2006-06-16 2014-06-12 리제너론 파마슈티칼스 인코포레이티드 유리체내 투여에 적당한 ｖｅｇｆ 길항제 제형
PE20090329A1 (es) 2007-05-30 2009-03-27 Abbott Lab Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
TWI580694B (zh) 2007-11-30 2017-05-01 建南德克公司 抗-ｖｅｇｆ抗體
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
EP2307458B1 (en) 2008-06-25 2018-04-11 ESBATech, an Alcon Biomedical Research Unit LLC Humanization of rabbit antibodies using a universal antibody framework
HUE053548T2 (hu) 2008-06-25 2021-07-28 Novartis Ag Stabil és szolúbilis, TNF-gátló ellenanyagok
ES2793008T3 (es) * 2008-06-25 2020-11-12 Novartis Ag Anticuerpos estables y solubles que inhiben VEGF
WO2010006454A2 (en) 2008-06-30 2010-01-21 Esbatech, An Alcon Biomedical Research Unit Llc Functionalized polypeptides
EP2515941B1 (en) 2009-12-21 2019-11-13 F.Hoffmann-La Roche Ag Pharmaceutical formulation of bevacizumab
EP2648750B1 (en) 2010-12-10 2017-01-25 Novartis AG Antibody formulation
EP2663325A1 (en) * 2011-01-13 2013-11-20 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat angiogenic eye disorders
RU2013155695A (ru) * 2011-06-30 2015-08-10 Дженентек, Инк. Препараты антител против с-мет
EP3431495A1 (en) * 2011-10-20 2019-01-23 ESBATech - a Novartis Company LLC Stable multiple antigen-binding antibody
AU2013256092B2 (en) 2012-05-03 2017-11-23 Alcon Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
JOP20200175A1 (ar) 2012-07-03 2017-06-16 Novartis Ag حقنة
UA117466C2 (uk) * 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
MY189047A (en) 2013-03-13 2022-01-21 Genentech Inc Antibody formulations
WO2015086830A1 (en) * 2013-12-13 2015-06-18 Delenex Therapeutics Ag Skin penetrating polypeptides
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
BR112016029864A2 (pt) * 2014-06-17 2017-08-22 Clearside Biomedical Inc métodos e dispositivos para tratamento de desordens oculares posteriores.
TWI738632B (zh) 2014-11-07 2021-09-11 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
US20160144025A1 (en) 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
KR20200131839A (ko) 2018-03-16 2020-11-24 노파르티스 아게 안질환의 치료 방법
JP7089121B2 (ja) 2018-12-18 2022-06-21 ノバルティス アーゲー 高濃度の抗ｖｅｇｆ抗体を含有するタンパク質溶液製剤

Also Published As

Publication number Publication date
JP2017534638A (ja) 2017-11-24
IL280087B (en) 2022-02-01
TW202146049A (zh) 2021-12-16
AU2020244614B2 (en) 2023-06-01
KR102724014B1 (ko) 2024-10-31
PH12021550147A1 (en) 2023-01-23
IL251696A0 (en) 2017-06-29
KR20240161204A (ko) 2024-11-12
AU2015342815A1 (en) 2017-05-11
US12371481B2 (en) 2025-07-29
US20200270336A1 (en) 2020-08-27
TW201625221A (zh) 2016-07-16
JP2017538674A (ja) 2017-12-28
RU2020114917A (ru) 2020-05-22
CL2017001117A1 (es) 2018-01-26
CN114081951A (zh) 2022-02-25
MX2021006768A (es) 2021-07-15
PH12017500844B1 (en) 2021-05-05
AU2020220210A1 (en) 2020-10-01
SG11201702909QA (en) 2017-05-30
US10689438B2 (en) 2020-06-23
MX383399B (es) 2025-03-13
CA2966646A1 (en) 2016-05-12
IL265497B (en) 2021-06-30
RU2020114917A3 (show.php) 2022-01-17
SG10201913565RA (en) 2020-02-27
KR102588846B1 (ko) 2023-10-16
AU2020244614A1 (en) 2020-11-05
MY183807A (en) 2021-03-16
EP3215122A1 (en) 2017-09-13
JP6667519B2 (ja) 2020-03-18
IL251642A0 (en) 2017-06-29
SG11201702954XA (en) 2017-05-30
JP2025004075A (ja) 2025-01-14
AU2015342818B2 (en) 2019-01-03
CN107635580A (zh) 2018-01-26
PH12017500844A1 (en) 2017-10-30
KR20170076781A (ko) 2017-07-04
AU2018274882A1 (en) 2018-12-20
IL251642B (en) 2021-02-28
MY193913A (en) 2022-11-01
JP7080263B2 (ja) 2022-06-03
JP6753848B2 (ja) 2020-09-09
MX2017005874A (es) 2017-06-26
TWI738632B (zh) 2021-09-11
GT201700096A (es) 2019-10-10
NZ730821A (en) 2019-11-29
JP2020079242A (ja) 2020-05-28
WO2016073918A1 (en) 2016-05-12
WO2016073915A1 (en) 2016-05-12
ECSP17034829A (es) 2019-02-28
AU2020220210B2 (en) 2022-01-20
IL283561A (en) 2021-07-29
KR20230066649A (ko) 2023-05-16
AU2018278870A1 (en) 2019-01-03
JP2022141923A (ja) 2022-09-29
JP2020193212A (ja) 2020-12-03
US20160340420A1 (en) 2016-11-24
IL265497A (en) 2019-05-30
EP3215122B1 (en) 2025-08-13
US11098110B2 (en) 2021-08-24
TWI761959B (zh) 2022-04-21
IL280087A (en) 2021-03-01
BR112017008093A2 (pt) 2018-03-13
CO2017004596A2 (es) 2017-08-31
US20160130337A1 (en) 2016-05-12
EP3215122C0 (en) 2025-08-13
TWI806150B (zh) 2023-06-21
TWI705827B (zh) 2020-10-01
EA201790989A1 (ru) 2017-09-29
EP3215123A1 (en) 2017-09-13
BR112017008660A2 (pt) 2017-12-26
RU2722643C2 (ru) 2020-06-02
US12049495B2 (en) 2024-07-30
MX2017005875A (es) 2017-06-26
TW202103735A (zh) 2021-02-01
AU2018274882B2 (en) 2020-07-09
AU2015342815B2 (en) 2018-12-13
AU2015342818A1 (en) 2017-05-11
US20180298092A1 (en) 2018-10-18
IL283561B (en) 2022-01-01
TW201625306A (zh) 2016-07-16
US20210340242A1 (en) 2021-11-04
PE20170780A1 (es) 2017-07-04
RU2017119647A (ru) 2018-12-07
KR20170082526A (ko) 2017-07-14
AU2018278870B2 (en) 2020-05-28
CA2966758A1 (en) 2016-05-12
CN106999581A (zh) 2017-08-01
CL2017001115A1 (es) 2018-01-26
PH12017500843A1 (en) 2017-10-30
RU2017119647A3 (show.php) 2019-05-29
TN2017000128A1 (en) 2018-10-19
ES3051145T3 (en) 2025-12-26
CN120938921A (zh) 2025-11-14
US10035850B2 (en) 2018-07-31

Similar Documents

Publication Publication Date Title
MX383808B (es) Formulacion estable de proteina en solucion que contiene una alta concentracion de un anticuerpo anti-vegf.
CY1122181T1 (el) Φαρμακοτεχνικη μορφη αντισωματος
AR107014A1 (es) Formulación farmacéutica acuosa
CL2018003178A1 (es) Composición farmacéutica
EA201492021A1 (ru) Антительный состав
CL2021001587A1 (es) Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf
BR112016026811A2 (pt) formulação de anticorpo
BR112015022210A2 (pt) formulações farmacêuticas aquosas estáveis, seu uso, artigo de manufatura, métodos de redução da agregação de um anticorpo monoclonal terapêutico e método de produção de uma formulação farmacêutica.
AR091530A1 (es) Formulacion farmaceutica liquida de un anticuerpo y acetato
AR130115A2 (es) Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf
AR102572A1 (es) Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf